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treatment patterns, prices and data availability. This study aims
at developing a model to overcome these challenges and to
combine epidemiology and economic data to estimate the cost
of MS in Europe. METHODS: A model was developed, based
on the prevalence of the disease and the cost per patient for dif-
ferent degrees of severity of disease, with the following purposes:
1) transform and convert available economic data to a deﬁned
time period as well as currency; 2) adjust country speciﬁc eco-
nomic data for purchasing power and relative size of economy;
3) impute data for countries where no data are available; and 4)
combine epidemiology and economic data to estimate the total
cost of a deﬁned disease. The model was populated with Euro-
pean published data on multiple sclerosis. National and inter-
national statistics for the model were retrieved from the OECD
and Eurostat databases. The estimates were presented in Euro
for 2003. RESULTS: The estimated cost for MS in Europe is
10.7€ billion. Mild patients with MS accounted for 53% of the
total cost, moderate 25% and severe patients for 22%. The high
income countries accounted for 77% of the total cost and the
countries with high prevalence in MS constituted 80% of the
total cost. The model estimates for drug costs were validated
against other data on total costs for MS drugs in Europe. CON-
CLUSIONS: The model provides a novel approach to estimat-
ing the cost of illness of a disease in Europe, as illustrated with
the example of MS.
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OBJECTIVES: The lack of epidemiological data has suggested
to perform an Italian retrospective study with the objective to
assess the health resources consumption that are caused by
acromegalic cure and the relative co-morbidities in order to esti-
mate the amount of the direct cost of acromegalic patients.
METHODS: A retrospective study has been performed on a total
of 134 patients (142 patients selected, 76 patients by site of
Genoa and 66 patients by the site of Turin) for a period of about
7 years preceding the enrolment date. For the observation study
period all hospitalizations (ordinary hospitalization and Day-
Hospital), all specialist visits and diagnostic and laboratory tests
have been collected, for each patient, from the relative medical
records independently if the health care resources used were due
to the primary disease or to co-morbidities. Only direct costs
have been evaluated by performing an analysis on the perspec-
tive of Italian Healthcare Service (SSN). RESULTS: The mean
total direct costs for acromegaly cure ranged from 8,526 to
12,546€ €/year (p = 0.008, Mann Whitney Test), respectively, for
controlled and not controlled patients. Pointing out that the cost
driver was represented by drug (somatostatin analogs) for
acromegalic cure, the not controlled patient group showed a
major use of drugs and the relative mean annual cost was about
1.66 times than that of controlled patient group (mean annual
drug cost 6,438€ ± 8993 in the controlled group vs 10,719€ ±
10,012 in not-controlled group; p = 0.012). CONCLUSION:
The study support the hypothesis that controlled patients drove
a saving for SSN in comparison to poor control patients that use
more health resources.
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OBJECTIVES: To quantify the differences in health-related
quality of life within and between adults with GHD and the
general population in Spain and England & Wales (E&W),
respectively, using the disease-speciﬁc instrument QoL—Assess-
ment of Growth Hormone Deﬁciency in Adults (QoL-AGHDA).
METHODS: QoL-AGHDA is a 25-item questionnaire that
elicits yes/no responses to personal statements describing prob-
lems that characterize aspects of HrQoL in growth hormone deﬁ-
ciency. A high QoL-AGHDA score denotes poor HrQoL. The
Spanish population sample comprised 940 individuals, and the
England and Wales sample 921. These survey data were collected
in studies reported elsewhere (Badia and Koltowska–Häggström,
respectively). Patient data were retrieved from KIMS (Pﬁzer
International Metabolic Database). The number of patients from
the two countries were 315 and 836, respectively. Student t-tests
were performed on mean data for groups formed by 10-year age
bands and gender. RESULTS: For Spain the mean QoL-AGHDA
was 11.0 for patients and 5.1 in the general population. For
E&W the corresponding means were 14.7 and 6.7. The mean
deﬁcits for patients compared with the general population were
similar in all age- and gender groups and were statistically sig-
niﬁcant (p < 0.0001). The mean patient QoL-AGHDA from
E&W were signiﬁcantly higher in most age and gender categories
compared with the Spanish patients (p < 0.05). The general pop-
ulation QoL-AGHDA scores in men did not differ signiﬁcantly
between countries (Spain = 5.9 vs. E&W = 6.2), but women from
Spain scored signiﬁcantly lower (higher HrQoL) than women
from E&W (3.9 vs. 7.0; p < 0.0001). CONCLUSIONS: This
study conﬁrms the extent of deﬁcit in HrQoL in adults with
GHD compared to general population. For patient comparisons,
caution is needed in interpreting these results, since the eligibil-
ity criteria for GH replacement differ between the two countries.
The reasons for gender variability between Spain and E&W
general population requires further studies.
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OBJECTIVE: Adequate treatment of patients with overactive
bladder (OAB) depends signiﬁcantly on the rate of persistence
